A +3 variant at a donor splice site leads to a skipping of the MYH11 exon 32, a recurrent RNA defect causing Heritable Thoracic Aortic Aneurysm and Dissection and/or Patent Ductus Arteriosus

Abstract

Background

Pathogenic variants in MYH11 are associated with either heritable thoracic aortic aneurysm and dissection (HTAAD), patent ductus arteriosus (PDA) syndrome, or megacystis‐microcolon‐intestinal hypoperistalsis syndrome (MMIHS).

Methods and Results

We report a family referred for molecular diagnosis with HTAAD/PDA phenotype in which we found a variant at a non‐conserved position of the 5’ donor splice site of intron 32 of MYH11 potentially altering splicing (NM_002474.3:c.4578+3A>C). Although its cosegregation with disease was observed, it remained of unknown significance. Later, aortic surgery in the proband gave us the opportunity to perform a transcript analysis. This showed a skipping of the exon 32, an RNA defect previously reported to be translated to an in‐frame loss of 71 amino acids and a dominant‐negative effect in the smooth muscle myosin rod. This RNA defect is also reported in 3 other HTAAD/PDA pedigrees.

Conclusion

This report confirms that among rare variants in MYH11, skipping of exon 32 is recurrent. This finding is of particular interest to establish complex genotype–phenotype correlations where some alleles are associated with autosomal dominant HTAAD/PDA, while others result in recessive or dominant visceral myopathies.

We report on a family with heritable thoracic aortic aneurysm and/or dissection with patent ductus arteriosus (FTAAD/PDA) caused by a variant leading to a skipping of the exon 32 in the MYH11 gene. This transcripts defect previously shown to lead to a strong dominant negative effect in the smooth muscle myosin rod is recurrent. It highlights some unclear genotype‐phenotype correlations suggested by literature with some alleles associated with autosomal dominant FTAAD/PDA while others result in recessive visceral myopathies.

1. INTRODUCTION

Thoracic aortic aneurysms are mostly asymptomatic and tend to expand over time, which increases the risk for an acute ascending aortic dissection with a poor prognosis (Milewicz et al., 2017). One‐quarter to one‐third of patients with a personal and a familial history of non‐syndromic thoracic aortic disease has a pathogenic or likely pathogenic variant in a gene of heritable thoracic aortic aneurysm and dissection (HTAAD) (Arnaud et al., 2019; Mariscalco et al., 2018). In the absence of a familial history, the detection rate decreases to around 10% (Li et al., 2021). Identification of a variant in one of these genes is, therefore, important both to detect affected family members, but also to adapt patient surveillance and care. Rare variants affecting the coiled‐coil domain of the smooth muscle cell‐specific isoforms of the myosin heavy chain (encoded by MYH11) lead to HTAAD, mostly associated with patent ductus arteriosus (PDA) (Zhu et al., 2006; Milewicz et al., 2017, MIM#132900).

2. PATIENTS AND METHODS

2.1. Ethical compliance

Informed consent was obtained from all individual included in this study and the ethics committee of the Nîmes University Hospital approved the study (IRB‐21.03.04).

2.2. Clinical Report

We report a family referred for molecular diagnosis at our laboratory in 2016 with two siblings who presented type A aortic dissections (Figure 1, supplemental data).

FIGURE 1.

Pedigree of the family showing the segregation of the MYH11 c.4578+3A>C variant with the cardiovascular phenotype. Tested individuals are figured by a thick line

At 22 years old, the proband (III.2) had a type A aortic dissection extended to the femoral arteries and was treated by valve‐sparing root replacement (tricuspid valve). The chronic dissection monitored annually by CT scan was stable until the age of 46 years, when the patient suddenly presented with chest pain. The CT scan performed in emergency showed a progression with a dissecting aneurysm at the level of the descending aorta measured at more than 50 mm and a multitude of re‐entries between the true and false channel all along the aorta, in favor of an acute type B dissection. In addition, echocardiography revealed an aortic valve regurgitation. Therefore, he benefited from the frozen elephant trunk technique and Bentall procedure to treat both conditions (Bentall & de Bono, 1968; Borst et al., 1983).

His oldest sister (III.1) had a type A aortic dissection at 45 years old. Her medical history revealed high blood pressure, narrow lumbar canal, recurrent spontaneous right pneumothorax (first at 37 years old), and tobacco smoking. Immediately afterward a valve‐sparing aortic root replacement surgery in emergency (tricuspid valve), she developed a left middle cerebral artery stroke secondary to the occlusion of the M1 segment and an internal carotid dissection. This second dissection event was independent of the aortic dissection on imagery (supplementary material). A pathologic study report of the aorta noted “medial mucoid changes with foci of cystic medial degeneration, without atheromatous deposits or foci of parietal inflammation.” She kept important sequels with a grabby state, hemiplegia, aphasia, and loss of autonomy and died one year later in a palliative care unit. Previously, her father (II.3) had died suddenly at 28 years old without any known medical history and had no postmortem examination. The proband's daughter (IV.3) was diagnosed with a PDA in infancy and considered spontaneously closed at 3 years old. A recent transthoracic echocardiography and Doppler revealed normal aortic root diameters but an intermittent PDA. His son (IV.2) was asymptomatic at last follow‐up with normal diameters of the aortic root (Valsalva 30 mm, +0.7SD) and absence of PDA (19 years old). Family history did not reveal other members potentially affected by aortic disease.

2.3. Genetic Analyses

A targeted next‐generation sequencing (NGS) panel of 15 HTAAD genes (detailed methods and gene list in supplementary data) performed on patient III.2 DNA revealed the heterozygous c.4578+3A>C variant in MYH11 (NM_002474.3, SM1A transcript variant) or NC_000016.10:g.15721419T>G. This novel variant (submitted for public access through LOVD under accession ID: #0000736497, MYH11.lovd.nl) was absent from GnomAD, our own database (>1000 patients), and the literature. Multiple splicing prediction software predicted an alteration of a wild type 5’splice site (ss). These predictions were, however, lower than those for previously reported pathogenic variant at the same ss (Supplemental material). The variant segregated with the cardiovascular phenotype in the family, as it was found in all three affected members. One asymptomatic member (IV.2) was also heterozygous for the variant. This position is not conserved and a variant at the same position c.4578+3A>G is reported mostly as likely benign in the ClinVar database (rs143288748), with a frequency of around 0.14% in the general population (GnomAD) and splicing prediction software did not predict an alteration of the 5’ss (Supplemental material). No other variant of interest was identified in NGS data, and oligonucleotide microarray analysis did not reveal any unbalanced chromosomal anomaly in the DNA of patient III.2.

Aortic surgery of patient III.2 four years later gave us the opportunity to conduct the transcript analysis. We, therefore, performed total RNA extraction using RNeasy Mini Kit (Qiagen, Hilden, Germany) on uncultured aortic biopsy taken during surgery according to the manufacturer's instructions. RNA was also extracted using the same kit from cultured skin fibroblasts of a control patient. We then conducted a one‐step reverse transcription‐polymerase chain reaction (RT‐PCR) targeted to exons 31–33, and exon 32 to the 33–34 exon junction of MYH11. We used the GUS gene as a control (primers in supplementary data). Electrophoresis of the PCR product was performed with 4200 TapeStation System (Agilent Technologies, Santa Clara, California, USA) with D1000 DNA ScreenTape Analysis according to manufacturer protocol. Electrophoresis of the PCR product of exons 31 to 33 revealed one amplicon of the expected size (507 bp) and another about 200bp shorter (Figure 2a). For the PCR product of exons 32 to 33/34, electrophoresis displayed only one product of the expected size for (315bp). These data provide evidence for exon skipping of the 213 bp exon 32 of MYH11, which was confirmed by direct sequencing on an ABI 3500XL (Thermofisher Scientific)(Figure 2b). This variant results in a 213bp in‐frame deletion of exon 32 of the mature RNA (r.4366_4578del).

FIGURE 2.

RT‐PCR analysis demonstrates MYH11 c.4578+3A>C leads to exon 32 skipping. a. RT‐PCR products run on TapeStation System (Agilent Technologies). The expected 515‐bp wild‐type fragment was obtained in both the control (W) and the mutated individual (M); an additional 302‐bp fragment was found in the mutated individual. b. Electropherogram from ABI 3500xl DNA analyzer (Applied Biosystems) showing that the variant causes the skipping of the exon 32

3. DISCUSSION

We report a pedigree affected by HTAAD/PDA caused by a splice defect at a variable position +3 of a 5’ss of MYH11 intron 32. Although recent progress has been made, interpretation of variants that could affect the splicing outside the canonical or cryptic dinucleotide GT/AG splice sites is challenging because of imperfect and sometimes conflicting results obtained with in silico prediction software (Jaganathan et al., 2019). In particular, the pathogenicity of variants at the position +3 of 5’ss is difficult to predict: data in the literature report some variants as pathogenic and others as benign. Moreover, the influence of the nucleotide environment has been previously suggested (Guédard‐Méreuze et al., 2009). To illustrate this, we used currently available algorithms to calculate computational scores with known variants at this 5’ss (Supplemental material). Despite a tendency toward an effect for the pathogenic c.4578+3A>C variant compared to the likely‐benign c.4578+3A>G one (−11.4 to −59.6% variation vs −3.2 to −11.2%) in silico predictions do not allow a conclusion compared with the c.4578+1G>T/A/del variants. Thus, transcript analysis is mandatory to consider whether a +3 variant alters splicing or not.

Interestingly, the RNA defect caused by the c.4578+3A>C is the same as previously described about the c.4578+1G>T variant reported in a large HTAAD/PDA family (Khau Van Kien et al., 2004; Zhu et al., 2006). The authors visualized a shortened protein with a 71 amino acid deletion using immunoblotting of aortic tissue. This in‐frame deletion (p.1456_1526del) alters the coiled‐coil domain of the protein. In vitro and in vivo functional experiments were supportive of a dominant negative effect by altering the thick myosin filament formation. In addition to this family and the one we report here, we identified two more reports of HTAAD/PDA pedigrees with other variants predicted (c.4578+1G>A) or shown (c.4578+1delG) to lead to exon skipping of exon 32 (LaHaye et al., 2016; Renard et al., 2013).

Other HTAAD/PDA patients have rarely been reported in the literature with variants affecting the coiled‐coil domain or the ATPase head region (Pannu et al., 2007). Nonetheless, variant segregation seems to be imperfect in some individuals but functional studies that establish an effect on the protein have not been performed (Harakalova et al., 2013). Decreased penetrance like observed in patient IV.2 and literature is frequent and often age‐related. It is also the case for other HTAAD genes such ACTA2, TGFBR1 and TGFBR2 (Pannu et al., 2005; van de Laar et al., 2019).

Moreover, predicted loss‐of‐function variants of MYH11, including the 16p13.11 recurrent microdeletion, are associated with recessive MMIHS (Gauthier et al., 2015; Kloth et al., 2019). Three other variants predicted to result in an elongated protein, and a strong impairment of dimerization predicting loss‐of‐function, are reported in three dominant pedigrees affected by Chronic Intestinal Pseudo‐Obstruction or Myopathic Gastrointestinal Motility Disorder (Dong et al., 2019; Gilbert et al., 2020; Ikebe et al., 2001). In this context, MYH11 variants may lead to two main different categories of variable phenotypes of smooth muscle cell dysfunction (HTAAD/PDA and “visceral myopathies”) through two different pathogenic mechanisms. It is also interesting to note that the 16p13.11 duplication that encompasses MYH11 is associated with a 10‐fold increased risk of aortic aneurysm and dissection (Kuang et al., 2011; Milewicz et al., 2017). This copy number variant is commonly considered as a susceptibility factor to neurodevelopmental disorders with low penetrance (8.4%) and variable expressivity, found in the general population (Allach El Khattabi et al., 2020).

Collectively, these facts highlight the unclear MYH11 genotype/phenotype correlations that should be further studied and documented. As a first effort, our observation highlights that dominant HTAAD/PDA associated MYH11 alleles, and in particular, the recurrent exon 32 skipping (dominant negative) or TAAD susceptibility (hypermorph), may confer other properties than predicted loss‐of‐function MYH11 alleles (leading to recessive or dominant “visceral Myopathies”). Consequently, pathogenic assessment of a variant in the MYH11 gene in HTAAD/PDA should be particularly cautious and curation of MYH11 variants for specific disease phenotypes is critical due to differences in inheritance and mechanism. Further studies are necessary to evaluate several hypotheses that could explain the underlying pathophysiological mechanisms underlying these complex genotype/phenotype correlations. Among these hypotheses, loss or gain‐of‐function, effect of the variant on particular smooth muscle cells strains or their phenotype switch, effect on contraction or relaxation, mechanotransduction, signaling, etc., could be considered.

We provide here data from a new family with HTAAD/PDA, which highlights the unclear genotype‐phenotype correlations and molecular pathophysiological mechanisms observed in the few studies of MYH11. Skipping of the MYH11 exon 32 is a recurrent RNA defect leading to HTAAD/PDA. Transcript analyses should be considered in cases of variation in a +3 position of a 5’ss in any gene of interest to help the interpretation.

CONFLICT OF INTERESTS

The authors have no relevant financial or non‐financial interests to disclose.

AUTHOR'S CONTRIBUTION

BC, AP, GR, TLB and PKVK performed the genetic analysis; BC, BM, YD, TE, JP, MAM, SJ, ML, and PKVK evaluated for clinical data and follow‐up the family members; all the authors participated to the redaction of this manuscript.

Supporting information

Supplementary Material

Chesneau, B. , Plancke, A. , Rolland, G. , Marcheix, B. , Dulac, Y. , Edouard, T. , Plaisancié, J. , Aubert‐Mucca, M. , Julia, S. , Langeois, M. , Lavabre‐Bertrand, T. , & Khau Van Kien, P. (2021). A +3 variant at a donor splice site leads to a skipping of the MYH11 exon 32, a recurrent RNA defect causing Heritable Thoracic Aortic Aneurysm and Dissection and/or Patent Ductus Arteriosus. Molecular Genetics & Genomic Medicine, 9, e1814. 10.1002/mgg3.1814

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request. The genetic variant has been submitted for public access through LOVD under accession ID: #0000736497, MYH11.lovd.nl.